The following challenges always need to be addressed to recommend an appropriate Market Access Strategy

• Patient

  What is the burden of disease and who are the patients likely to benefit the most from the incoming product ?

• Treatment

  What is the standard of care for treatment of the pathology in the concerned countries ?

• Studies

  How should clinical studies be designed in order to meet the methodological prerequisites per country, considering local HTA requirements ?

• Benefits

  What are the benefits of the product in terms of efficacy, safety, convenience of use in comparison to current and upcoming therapeutic alternatives ?

• Opportunity

  Is there an opportunity for an early access program ?

• Pricing

  What can be expected in terms of added economic value vs. current treatments ?

• Negotiation

  What are the pricing scenarios and likelihood of reimbursement ?

AEC Partners can help you optimize your market access strategy

The main challenge today is to evaluate the added medical value that a new product must demonstrate to ensure a successful price and reimbursement negotiation.

We propose to conduct a structured and methodological approach that will clearly define :

• current requirements for success in EU 5
• most appropriate market access strategy and action plan for HTA assessment and pricing negotiation.

• At European (EU5)

  • •Maximize product chances of success by integrating market access levers during early development (phase 1 et 2)
  • •Based on our European expert network, define, test and validate your market access strategies upstream (Willingness to Use and Willingness to Pay)
  • •Develop the Payer Value Proposition

• Or local level

  • •Challenge and validate sales forecasts based on epidemiology and market modelling
  • •Perform, support or audit the market access strategy, dossiers for HTA bodies and the negotiation approach
  • •Assist through the whole negotiation phase at a local level

Why choose AEC Partners

• Successful bottom-up approach with senior experts and a dedicated team
  • Highly experienced and dedicated team for market access activities
  • A systematic senior presence at every phase of the project
  • Start with local issues to find tailored solution at a European level
  • Analytical and pragmatic approach
• Strong experience in defining market access strategies
  • More than 300 assignments supporting big, mid-size pharma and medical device companies in market access strategies
  • Trained to manage complex situations
  • Strong expertise in orphan and onco-hematology products
• Local implementation and assistance through the whole negotiation process
  • From European strategy to local dossier writing and submission (including logistics)
  • Deep knowledge regarding payers expectations
  • Assistance from early access program to P&R deal with local authorities